Home > Insider Trading > Filing (0001209191-14-043672)

Filing Details

Accession Number:: 0001209191-14-043672
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2014-06-25 19:30:30
Reporting Period:: 2014-06-23

Filing Date:: 2014-06-25
Accepted Time:: 2014-06-25 19:30:30
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1459266	Zs Pharma Inc.	ZSPH	Pharmaceutical Preparations (2834)	263305698

Insiders

Cik	Name	Reported Address	Director	Officer	Large Shareholder	Other
1356034	Devon Park Bioventures Lp	1400 Liberty Ridge Drive, Suite 103 Wayne PA 19087	No	No	Yes	No
1610919	Devon Park Associates, L.p.	1400 Liberty Ridge Drive, Suite 103 Wayne PA 19087	No	No	Yes	No
1610920	Devon Park Associates, Llc	1400 Liberty Ridge Drive, Suite 103 Wayne PA 19087	No	No	Yes	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Common Stock	Acquisiton	2014-06-23	1,422,901	$0.00	1,432,649	No	4	C	Direct
Common Stock	Acquisiton	2014-06-23	824,913	$0.00	2,257,562	No	4	C	Direct
Common Stock	Acquisiton	2014-06-23	168,910	$0.00	2,426,472	No	4	C	Direct
Common Stock	Acquisiton	2014-06-23	160,000	$18.00	2,586,472	No	4	P	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	C	Direct
No	4	C	Direct
No	4	C	Direct
No	4	P	Direct

Reported Derivative Transactions

Show Other Fields >>

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Series B Preferred Stock	Disposition	2014-06-23	1,422,901	$0.00	1,422,901	$0.00
Common Stock	Series C Preferred Stock	Disposition	2014-06-23	824,913	$0.00	824,913	$0.00
Common Stock	Series D Preferred Stock	Disposition	2014-06-23	168,910	$0.00	168,910	$0.00

Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
No	4	C	Direct
No	4	C	Direct
No	4	C	Direct

Reported Non-Derivative Holdings

Sec. Name	Remaning Holdings	Nature of Ownership	Explanation
Common Stock	9,748	Indirect	See Footnote

Footnotes

Devon Park Associates, L.P. is the holder of record of 9,748 shares of common stock of the Issuer ("Common Stock"). Devon Park Associates, LLC is the general partner of Devon Park Associates, L.P., which is the general partner of Devon Park Bioventures, L.P. Messrs. Marc Ostro, Christopher Moller and Devang Kantesaria are the founding members and managing directors of Devon Park Associates, LLC. Each such founding member (the "Founding Member") may be deemed to have shared voting and investment power over the shares beneficially owned by Devon Park Associates, L.P. and Devon Park Associates, LLC as described above. Each Founding Member disclaims beneficial ownership of these securities, except to the extent of his pecuniary interest therein, and this report shall not be deemed an admission that the Founding Members are the beneficial owners of such securities for Section 16 or any other purpose.
Devon Park Bioventures, L.P. is the holder of record of shares of Series B Preferred Stock, Series C Preferred Stock, Series D Preferred Stock ("Preferred Stock"), shares of Common Stock issued upon conversion of the Preferred Stock and the 160,000 shares of Common Stock purchased as reported by this Form 4. Devon Park Associates, LLC is the general partner of Devon Park Associates, L.P., which is the general partner of Devon Park Bioventures, L.P. The Founding Members are the managing directors of Devon Park Associates, LLC and each such Founding Member may be deemed to have shared voting and investment power over the shares beneficially owned by the funds as described above. Each Founding Member disclaims beneficial ownership of these securities, except to the extent of his pecuniary interest therein, and this report shall not be deemed an admission that the Founding Members are the beneficial owners of such securities for Section 16 or any other purpose.
The shares of Preferred Stock were converted into shares of Common Stock on a 1-for-1 basis immediately prior to the closing of the Issuer's initial public offering and has no expiration date.